EFFICACY OF CORAXAN AND FINOPTIN IN THE TREATMENT OF ANGINA ON EXERTION
The objective of the study was to compare the antianginal and antiischemic efficacy of Coraxan and Finoptin in patients with exertion stable angina and intolerance and/or contraindications to the use of β-adrenoblockers. Following 3-month therapy, the antianginal effect of Coraxan in a dose of 10-15 mg/day was comparable with that of Finoptin in a dose of 240 mg/day, by significantly improving quality of life indicators. Coraxan produced no negative effect on the basic parameters of 24-hour ECG monitoring.